Archives: Articles

The global market for ophthalmic eye droppers is expected to grow due to the rising rates of eye diseases such as glaucoma, dry eye disease, and age-related macular degeneration. Various packaging advancements for eye drops have occurred over time. Currently, manufacturers are exploring multidose bottles that safely dispense unpreserved drops without contamination. Regulatory approvals for these products have become more common, emphasizing the importance of maintaining sterility. There are opportunities for innovation, particularly in eco-design, focusing on reducing plastic use and water consumption; and in digital technology, utilizing sensors, AI and telemedicine to improve patient adherence and care.
Future innovations may include alternative delivery methods to improve treatment efficacy and management of eye diseases. This article aims to discuss the Ophthalmic Drug Delivery Latest Development.

Patient safety across the lifecycle of a medicine depends on vigilant monitoring of medical literature – not just well-known global sources, but also at a local level, where population-specific adverse events are most likely to come to the surface. Up to now, this has been a frustratingly laborious activity yielding modest, if vital, findings. It follows that technology-enabled process innovation may have something important to offer. Biologit’s Nicole Baker explores the potential to systematically and cost-efficiently scan the widest available spectrum of local sources – through optimised use of intelligent automation, overseen and governed by human experts.

This article explores the challenges of targeting G protein-coupled receptors (GPCRs) in drug discovery due to their complex structures and dynamic nature. It highlights the limitations of traditional small-molecule drugs and the complexities of developing antibody-based therapeutics. GenAI can overcome long-standing obstacles in targeting GPCRs, reducing timelines, and addressing unmet clinical needs, marking a new era in therapeutic possibilities. This article aims to demonstrate how Generative AI (GenAI) offers a solution by analysing large datasets to design precise, epitope-specific antibodies, thereby accelerating the drug discovery process.

Digital ambitions remain high across pharma Clinical, Regulatory, Quality, and Pharmacovigilance operations. The evolution from document- to data-based operations, and the need to fulfil expanded regulatory requirements, create new expectations around modern systems and inputting data in a consistent and compliant way. It is in this context that digital adoption platforms are gaining traction – proving timely, in-app user guidance. MAIN5’s Sabine Gölden explains.

Catalysts based on Platinum Group Metals (PGMs: Pd, Pt, Rh, Ir, Ru) play a fundamental role in modern civilization, enabling modern life in most aspects from food to travel to medicines. However, concerns about the security of supply and the environmental impact of mining are driving a trend towards the replacement of PGM catalysts. In this paper we provide an analysis of the sustainable use of PGMs, which accounts for the current and future shift in PGM availability and the true extent of PGM recycling. The actual contribution of PGMs to the carbon footprint of a model catalytic process is described in a simplified LCA case study, showing how the footprint of the whole catalytic step, rather than the catalytic metal in isolation, must be considered. The use of PGM catalysts, especially when effectively recycled, can provide more environmental value than generally perceived.

Natural deep eutectic systems (NADES) which have gained increasing scientific interest and the attention of the scientific community is beginning to be directed towards understanding the characteristics of these liquids that make them extremely particular. NADES are essentially formed through hydrogen bond interactions, between a hydrogen-bond donor compound and a hydrogen bond acceptor compound. The arrangements of different molecules that can constitute different NADES are estimated to be around 106 possible combinations (in the case of only binary mixtures). This article aims to present NADES and their applications, as well as describe their main characteristics in terms of their physicochemical properties. In addition, new developments in relation to the state of the art on the exploitation of their properties as solvents in applications such as extraction, (bio)catalysis and synthesis of pharmaceuticals, agrochemicals, functional materials or other high-added value substances with be discussed. Advances in different research areas have been notable in the last 10 years, boosting fundamental and basic research on NADES.

Enzyme immobilization is a critical technology to enhance the stability and reusability of biocatalysts for industrial applications. However, traditional immobilization development is still tied to trial-and-error approaches, which are time-consuming and often lead to a suboptimal preparation. In this article, we aim to discuss the latest developments in the integration of high throughput experimentation, bioinformatics and data driven tools for the design and development of novel immobilized enzymes.